CJC-1295 / Ipamorelin Combination

Overview

The CJC-1295 / Ipamorelin combination represents the most commonly referenced growth hormone secretagogue "stack" in contemporary research literature. This pairing combines two peptides with complementary mechanisms of action: CJC-1295 (No DAC), a modified analog of growth hormone-releasing hormone (GHRH) that activates GHRH receptors on pituitary somatotrophs, and Ipamorelin, a selective ghrelin receptor (GHS-R) agonist that mimics ghrelin's GH-releasing signal.

The scientific rationale for combining these peptides is grounded in fundamental endocrinology: simultaneous stimulation of both the GHRH and ghrelin signaling pathways produces a synergistic growth hormone (GH) release that exceeds what either peptide produces alone-published research suggests 2–3x elevation in GH levels compared to single-agent use.

Important historical context: CJC-1295 with Drug Affinity Complex (DAC) was under clinical development by ConjuChem Biotechnologies but development was discontinued following adverse events in Phase 2 trials. The "No DAC" version (Modified GRF 1-29) is the predominant form discussed in current research contexts. Neither formulation has obtained FDA approval, and both remain subjects of ongoing research rather than established therapeutics.

FDA Status & Regulatory Background

CJC-1295 Clinical Development

CJC-1295 with DAC (Drug Affinity Complex) was being developed by ConjuChem Biotechnologies under an active Investigational New Drug (IND) application. This longer-acting formulation was designed to provide sustained GH elevation through a Drug Affinity Complex that extended its pharmacological half-life. However, clinical development was discontinued following adverse safety events identified during Phase 2 trials. The company subsequently faced financial difficulties and did not pursue further regulatory pathways for this compound.

CJC-1295 (No DAC) / Modified GRF 1-29

The "No DAC" version, chemically identical to Modified GRF 1-29, has not undergone FDA clinical trials as a standalone therapeutic. It remains in the research domain, where it is sometimes available through compounding pharmacies depending on current FDA guidance on peptide compounding. No active IND exists for this formulation.

Ipamorelin Regulatory Status

Ipamorelin has been studied in human pharmacokinetic and pharmacodynamic trials but has not pursued FDA approval. It remains in the research/investigational category without an active development program toward FDA marketing authorization.

The combination of CJC-1295 (No DAC) and Ipamorelin has no published clinical trials and no regulatory pathway. Any discussion of this combination exists entirely within the research and laboratory context.

How the Combination Works: Mechanism of Action

CJC-1295 (No DAC) / Modified GRF 1-29: The GHRH Pathway

CJC-1295 (No DAC) is a 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH). It incorporates four amino acid substitutions designed to confer resistance to dipeptidyl peptidase IV (DPP-IV), an enzyme that degrades native GHRH. These modifications extend its in vivo activity compared to unmodified GHRH.

Mechanistically, CJC-1295 (No DAC) binds to GHRH receptors on the anterior pituitary's somatotroph cells, stimulating the intracellular signaling cascade that triggers GH secretion. Because this formulation lacks the DAC component, it has a shorter half-life (approximately 30 minutes) and produces pulsatile GH release patterns that more closely resemble endogenous GH pulsatility compared to the sustained release produced by the DAC variant.

Ipamorelin: The Ghrelin Pathway

Ipamorelin is a pentapeptide (five amino acids) that functions as a selective growth hormone secretagogue receptor (GHS-R) agonist. It mimics the natural hormone ghrelin's action on GHS-R, but with critical pharmacological distinctions. Unlike other synthetic GHSPs such as GHRP-6 or GHRP-2, Ipamorelin demonstrates high selectivity for GHS-R at physiological doses and does not significantly elevate cortisol, prolactin, or appetite-effects that are characteristic of non-selective GHSPs.

Ipamorelin acts as an "amplifier" of pituitary GH secretion, particularly potentiating the signal initiated by GHRH. This is the mechanistic basis for the synergistic effect observed when both peptides are co-administered.

Synergistic Effect: GHRH + GHRP = Enhanced GH Release

The synergistic amplification observed with GHRH + GHRP co-administration has been established in research literature as a fundamental principle of somatotroph physiology. When both pathways are simultaneously activated, the combined signal produces GH pulses significantly greater than additive responses, demonstrating true synergy at the level of pituitary secretion.

Published Pharmacokinetic Data

CJC-1295 with DAC

The most extensive human pharmacokinetic data comes from studies of CJC-1295 with DAC, the longer-acting formulation that completed Phase 2 trials before development was discontinued. Research published by Teichman et al. (Journal of Clinical Endocrinology & Metabolism, 2006) demonstrated that a single subcutaneous injection of CJC-1295 with DAC produced sustained elevation in GH levels for 6–8 days. Mean GH concentrations increased 2–10 fold, and insulin-like growth factor 1 (IGF-1) levels increased 1.5–3 fold. These pronounced and sustained elevations reflected the extended half-life imparted by the DAC modification.

It is important to note that the pharmacokinetics of the "No DAC" version (Modified GRF 1-29) are substantially different, with a much shorter duration of action and more pulsatile GH release patterns.

Ipamorelin Pharmacokinetics

Human pharmacokinetic and pharmacodynamic data for Ipamorelin come principally from studies by Raun et al. (1998) and Anderson et al. (2001). Raun's work demonstrated that Ipamorelin selectively stimulates GH release without the secondary elevations in cortisol and prolactin seen with other GHSPs-a distinction that has made it attractive for research settings. Anderson et al. characterized the time-course and dose-response relationships in human subjects, establishing that Ipamorelin produces relatively rapid GH stimulation following injection.

The serum half-life of Ipamorelin is short (approximately 2–3 hours), requiring multiple daily administrations to maintain continuous pulsatile stimulation patterns.

Combination Pharmacokinetics

Published pharmacokinetic data specifically investigating the CJC-1295 (No DAC) + Ipamorelin combination is limited. Most evidence for the synergistic GH-releasing effect comes from broader research on GHRH + GHRP interactions rather than this specific combination. In published studies of GHRH + GHRP co-administration (across various GHRH analogs and GHSPs), the combined administration typically produces GH peak concentrations that are 2–3 fold higher than either agent alone, and the duration of elevated GH may be extended compared to single-agent use.

Clinical Development: Why It Was Discontinued

ConjuChem Biotechnologies initiated clinical development of CJC-1295 with DAC under an IND application. The compound progressed through Phase 1 and into Phase 2 trials investigating its use in conditions associated with GH deficiency or age-related decline. However, clinical development was discontinued when adverse safety events were identified during Phase 2 testing.

This discontinuation represents an important historical reality: CJC-1295 did not complete the full clinical trial pathway necessary to establish adequate safety and efficacy profiles for FDA approval. The compound never reached Phase 3 trials, and ConjuChem subsequently faced financial challenges that prevented resumption of development.

Dosing Ranges in Research Literature

The following dosing information is derived from research literature and in vitro studies. These are not recommendations but rather documentation of dosing ranges that appear in the scientific literature and research protocols.

CJC-1295 (No DAC) Dosing

• Injection dose range: 100–300 micrograms (mcg) per injection
• Frequency in research: Typically studied at 1–3 times daily
• Route: Subcutaneous injection
• Administration timing: Often studied in the evening to augment the natural nocturnal GH surge

Ipamorelin Dosing

• Injection dose range: 100–300 micrograms (mcg) per injection
• Frequency in research: Typically studied at 1–3 times daily
• Route: Subcutaneous injection
• Administration timing: Often combined with CJC-1295 before bed; some protocols study pre-workout or morning administration

Common Research Protocol

A frequently referenced research protocol combines 100 mcg of CJC-1295 (No DAC) with 100 mcg of Ipamorelin in a single injection, administered subcutaneously before bedtime. This timing is designed to augment the natural, nocturnal surge in GH secretion that occurs during the early phases of sleep. Research cycles typically last 8–12 weeks, with 4–8 week breaks between cycles in investigational settings.

Reported Side Effects & Safety Considerations

Research and investigational use have associated the CJC-1295/Ipamorelin combination with the following reported effects. Because this combination has not undergone formal clinical trials as a paired product, incidence rates are estimated from individual component data and community reports.

Theoretical Long-Term Concerns

Chronic elevation of GH and IGF-1 raises theoretical concerns regarding carpal tunnel syndrome, glucose intolerance, and potential effects on cellular proliferation. Some research literature discusses a theoretical association between chronically elevated IGF-1 and increased cancer risk, though this remains contested and is not definitively established. Any long-term safety profile assessment would require data from controlled prospective trials, data that does not currently exist for this combination.

Comparison to Other GH Secretagogues

The following section places the CJC-1295/Ipamorelin combination in context with other GH-stimulating compounds and approaches discussed in research literature.

CJC-1295/Ipamorelin vs. Tesamorelin

Tesamorelin is an FDA-approved GHRH analog used clinically for HIV-associated lipodystrophy. Like CJC-1295, it targets GHRH receptors, but it has undergone the full FDA approval process and has established safety/efficacy data. Tesamorelin is long-acting and is administered once daily via subcutaneous injection. The CJC-1295/Ipamorelin combination offers the potential advantage of dual-pathway stimulation (GHRH + ghrelin), whereas Tesamorelin acts only on GHRH receptors. Tesamorelin is the only GHRH analog with FDA approval and established clinical use.

CJC-1295/Ipamorelin vs. GHRP-6 / GHRP-2

GHRP-6 and GHRP-2 are synthetic peptide GHS-R agonists that have been studied extensively. Both are potent GH secretagogues, but they are less selective than Ipamorelin. At physiological doses, GHRP-6 and GHRP-2 produce secondary increases in cortisol, prolactin, and appetite-effects that are characteristic of their broader pharmacological profiles. Ipamorelin's selectivity for GHS-R (without secondary hormone release) is considered an advantage in research settings seeking to isolate the GH-releasing effect.

CJC-1295/Ipamorelin vs. MK-677 (Ibutamoren)

MK-677 (Ibutamoren) is an oral GHS-R agonist that has advanced further in clinical development than any peptide GHS-R agonist. It is structurally distinct (small-molecule non-peptide) and offers the advantage of oral bioavailability. However, MK-677 also produces increases in prolactin and appetite similar to non-selective GHSPs. The peptide combination (CJC-1295/Ipamorelin) offers pulsatile GH release more closely resembling physiological patterns, whereas MK-677 may produce more sustained elevation.

CJC-1295/Ipamorelin vs. Sermorelin

Sermorelin is another GHRH analog (a 29-amino acid peptide identical to native GHRH, without DPP-IV resistant modifications) that has been available through compounding pharmacies. Like CJC-1295 (No DAC), it acts on GHRH receptors, but it lacks the amino acid modifications that confer DPP-IV resistance, resulting in a shorter duration of action. Sermorelin is sometimes used as a single agent in research; combination with Ipamorelin follows the same synergistic rationale as CJC-1295/Ipamorelin.

Why CJC-1295/Ipamorelin Is the Most Studied Combination in Research

The CJC-1295 (No DAC) / Ipamorelin combination has become the most frequently referenced GH secretagogue stack in research literature for several reasons:

• Complementary mechanisms: The pairing of GHRH and ghrelin pathway agonists produces documented synergistic GH release.
• Clean side effect profile: Ipamorelin's selectivity avoids secondary hormone elevations (cortisol, prolactin) and pronounced appetite stimulation characteristic of non-selective GHSPs.
• Pulsatile release pattern: The shorter half-life of CJC-1295 (No DAC) promotes physiological pulsatile GH secretion rather than sustained elevation.
• Research accessibility: Both peptides have been available through compounding pharmacies and research sources, making the combination more accessible than other options.

Frequently Asked Questions